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Evolution is a natural event that enables the animal and plant kingdoms to adapt and survive 
to changing environmental effects. The same evolutionary pressures also help to shape 
microorganisms including viruses. The evolutionary significance of virus infections has been 
a subject of discussion for decades;2 however, modern genomic analysis became an important 
focus of research when it became apparent that genetic variants of viruses could be linked to 
pathogenesis and disease progression. The first questions relating virus diversity to disease 
progression were provided by Pierre Lépine in 1938 who reported on the evolution of 
different strains of rabies viruses and a link between different characteristics of infectivity and 
virulence.3 Recent reports have also revealed the importance of viral evolution and genetic 
diversity in the pathogenesis of viral diseases in particular of RNA- (influenza virus, HCV)4, 5 
and retrovirus infections (HIV).6 Hepatitis B virus (HBV) utilizes a reverse transcription 
strategy that together with an error-prone viral polymerase has the potential to generate a 
large number of genetic variants. Chronic HBV (CHB)-infection follows four complex 
dynamic phases, namely immune tolerance, immune clearance, immune control/inactive state, 
and immune escape/reactivation that evolve over several decades. This scenario is usually 
accompanied by HBeAg-seroconversion. The frequency and severity of hepatitis flares can 
predict disease progression while early HBeAg-seroconversion confers a favorable outcome 
and late or absent HBeAg-seroconversion results in progression to severe liver disease, such 
as cirrhosis. The underlying mechanism leading to HBeAg-seroconversion is thought to be 
mainly due to immunologically mediated events. HBeAg-negative disease is often associated 
with the selection of precore/core mutations that develop because of immune pressure during 
immune clearance.7, 8 However, studies of viral diversity and its association with viral 
evolution are infrequent and attempts to explain mechanisms leading to HBeAg-
seroconversion remain speculative. 
In their paper published in GUT, Cheng and colleagues shed new light on the relationship 
between virus diversity, cumulative evolutionary changes and HBeAg-seroconversion in CHB 
(see page XX).1 They carefully explored the long term progression of HBV quasi-species 
relative to the time point of HBeAg-seroconversion. By performing a follow-up study (up to 
ten years) using preserved serum samples of CHB-patients, the viral diversity of HBeAg-
seroconverters was compared with non-seroconverters. In order to determine the initiation of 
viral evolution during CHB the authors estimated HBV-diversity by using pairwise distances 
under a general time reversible (GTR) model of nucleotide evolution. They observed a 
gradual increase of viral diversity in seroconverters that started seven years before HBeAg-
seroconversion occurred. Increases in viral diversity were accompanied by a generally higher 
evolutionary rate in seroconverters resulting in more distantly related virus species as 
illustrated in their phylogenetic analysis. 
Cheng and colleagues then addressed the question of whether there is a preferred 
localization of sequence variations in the HBV-genome during viral evolution. Remarkably, 
genetic diversity was localized predominantly to the non-overlapping precore/core region 
whereas overlapping regions of the HBV-genome did not show a significant increase of 
diversity. Concomitant with rising viral diversity, the appearance of the precore stop codon 
mutation at nt1896 was significant more frequent in HBeAg-seroconverters before the 
development of HBeAg-seroconversion. These findings together with the decline of viral load 
and HBeAg-level years before HBeAg-seroconversion favors the hypothesis that increasing 
immune pressure leads to changes within the precore/core protein. Previous reports confirm 
this hypothesis showing that HBV-core promoter mutants (A1762T/G1764A and 
C1766T/T1768A) are predominant in late stage of HBeAg-seroconversion and can have 
major impact on HBV-replication and HBeAg-expression.7 Although the exact role of core 
promoter and precore stop mutations on HBeAg-seroconversion remains to be elucidated, at 
least some contribution is likely.  
The authors also reported on the observation of positive selection of amino acid (aa) 
substitutions at certain positions of the core antigen. In general, positive selection of aa-
substitutions might occur as a result of a replication advantage or immunological pressure.9 
Recent observations have shown a link between increasing viral diversity and the selection of 
several aa-changes in known T-cell epitopes during immunoclearance phase.8 Cheng et al. 
described five positions that are positively selected only in HBeAg-seroconverters (P5T, 
V13S, I27V, L60V, P135Q). While up to 100% of the sequences of individual patients are 
carrying at least one positive selected aa, approximately 40% had two or three positive 
selected sites. The observation of positive aa-selection is in line with a recently published 
study.10 Here, Cheng and colleagues demonstrated that respective aa-substitutions can occur 
years before HBeAg-seroconversion.  
The appearance of these aa-substitutions during the immune clearance phase was also 
described in 1996; however, a correlation with HBeAg-seroconversion was not noted.11 
Subsequently, cell culture experiments using recombinant HBV-genomes bearing single 
mutations at either position P5 or L60 revealed an extracellular phenotype with significantly 
reduced virion secretion but normal intracellular viral replication.12 Despite a potential 
disadvantage for the virus, like diminished secretion, it could be assumed that sufficient 
pressure may drive the virus to evolve towards the selection of aa-changes within specific 
sites. Since these arising mutations remain stably integrated after HBeAg-seroconversion the 
hypothesis of immune escape mutations seems to be well supported.        
Cheng and colleagues have analysed 2,600 sequences in order to substantiate their 
hypothesis. Although cumulative viral evolutionary changes appear to precede HBeAg-
seroconversion, next generation sequencing (NGS) will bring additional and substantial in-
depth information. NGS may help to identify molecular processes leading to the onset of 
specific genetic changes in coding and core promoter regions during the natural course of 
CHB and during antiviral treatment.  
How does the study of Cheng and colleagues help us to understand the role of HBV 
diversity, the emergence of precore/core variants in the scope of cumulative viral evolution 
during HBeAg-seroconversion and thus affecting antiviral treatment success and outcome of 
liver disease? First, the authors demonstrated that the increase in HBV quasi-species is linked 
to mutations occurring predominantly in the HBV precore/core region. They hypothesized 
that specific immune pressure on T-cell epitopes may alter tolerance of CD4/CD8 T-cell 
reactivity whereas increased viral diversity can be responsible for stimulating the innate 
immune system. Of significance the selection of a greater number of sites in T-cell epitopes 
has recently been described supporting their role in host immunity.8 Secondly, mutations in 
the precore/core region can influence HBV capsid stability which in turn can affect virus 
maturation, virus secretion and viral load. Accordingly, complex immune- (alteration of 
immune response) and virus-mediated processes (replication fitness) can interact in harmony 
in shaping HBV evolution.8  
The findings provided by Cheng et al. add new insights to our knowledge of the complex 
processes of viral evolution, viral diversity, and selection of HBV quasi-species in chronic 
hepatitis B. We are still at the beginning of understanding these processes of viral evolution 
and the association with pathogenesis in general and in particular with CHB and HBeAg-
seroconversion. However, from the perspective of the HBV, viral evolution generating well 
adapted viral quasi-species is a perfect strategy to assimilate to changing environments 
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